Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
  • Peer groups
    • HR Peer Group
    • Recruitment Peer Group
    • Marketing Peer Group
    • PA Peer Group
More
    • Contact us
    • Join the network
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job
    • Peer groups
      • HR Peer Group
      • Recruitment Peer Group
      • Marketing Peer Group
      • PA Peer Group

    Breadcrumb

    1. Home
    2. News
    3. Search results
    Displaying results 201 - 225 of 673 Clear search
    Zyme Communications
    Lucas Paulo de Lima Camillo, Head of Machine Learning, Shift Bioscience
    Healthcare and Life Science 01 Jul 2025

    Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery

    Study identifies new metrics to enhance scRNA-seq based virtual cell modellingFoundational paper to drive development of improved virtual cell models for rejuvenation target discovery

    Cambr

    Zyme Communications
    Heikki Lanckriet, CEO,  4basebio
    Healthcare and Life Science 01 Jul 2025

    4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies

    4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today (01 July 2025) announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.

    Zyme Communications
    The Zyme Communications team
    Healthcare and Life Science 26 Jun 2025

    Zyme Communications celebrates 15 years of providing specialist support for the life science sector

    Zyme Communications Ltd. (Zyme), the life science specialist PR and marketing agency, today (26 June 2025) celebrates its 15-year anniversary, and introduces refreshed branding to reflect this milestone and the Company’s continued development.

    Zyme Communications
    Dr. Dan Turner, CSO, Enhanced Genomics	Dr. John Skidmore, CSO, The ALBORADA Drug Discovery Institute	Dr. Julia Dudley, Head of Strategic Programmes, Alzheimer’s Research UK
    Healthcare and Life Science 24 Jun 2025

    Enhanced Genomics and The ALBORADA Drug Discovery Institute partner to accelerate Alzheimer's drug discovery

    Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of

    Zyme Communications
    Dr Julian Gough,  CEO and Founder, OutSee 	Dr Paul Wallace, Chair, OutSee
    Healthcare and Life Science 24 Jun 2025

    OutSee raises £1.8M seed funding to expand therapeutic pipeline using predictive genomics

    Financing led by Ahren Innovation Capital with additional investment from Kadmos Capital, Empirical Ventures and Panacea VenturesInvestment to leverage OutSee’s proprietary AI-based predictive genomics technology, Nomaly, to expand and progress in-house target developme
    Zyme Communications
    Bio-Rad anti-idiotypic antibodies
    Healthcare and Life Science 17 Jun 2025

    Bio-Rad extends anti-idiotypic antibody and SpyCatcher Reagent ranges for bioanalysis and antibody drug development

    Additions to Company’s Range of Bioanalytical Antibodies and Reagents Enhances Bioanalysis and Antibody-Related Research

    Zyme Communications
    AI image simulation of a human lung created from historic imaging data
    Healthcare and Life Science 17 Jun 2025

    Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

    AI-enabled analytics platform demonstrates how real-world data used in place of human placebo and control groups can significantly reduce study costs and duration

    Zyme Communications
    AI Precision Medicine Platform
    Healthcare and Life Science 17 Jun 2025

    Mursla Bio introduces AI precision medicine platform built on organ-specific EV isolation from blood

    Platform is built on biologically labelled, organ-specific multi-omics data carried by extracellular vesicles isolated from 2ml plasma samplesEnables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, su
    Zyme Communications
    David Fairlamb, Chief Development Officer, SolasCure
    Healthcare and Life Science 16 Jun 2025

    SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers

    Recognises the potential of Aurase Wound Gel to improve outcomes for individuals with calciphylaxis ulcers, a rare and life-threatening conditionRepresents a new indication for Aurase Wound Gel, currently in Phase II Clinical Trials for treatment of venous leg ulcers
    Zyme Communications
    https://www.kadans.com/
    Healthcare and Life Science, Property and Utilities, Science and Engineering 13 Jun 2025

    Kadans Science Partner completes construction of primary structure on purpose built laboratory building at Merlin Place, North Cambridge

    Topping out ceremony gathered key stakeholders on Cambridge Wide Open Day to celebrate progress in development of new laboratory facilities139,000 sq ft of flexible lab and office space, due for completion Q3 2026

    Cambridge, UK, 13 June 2025:

    Zyme Communications
    Dietrich Stephan, Ph.D., Chair, Enhanced Genomics
    Healthcare and Life Science 10 Jun 2025

    Enhanced Genomics appoints Dietrich Stephan, Ph.D. as Chair of the Board to lead ambitious growth strategy

    Appointment strengthens leadership team to drive strategy focused on harnessing 3D multi-omics to identify high-confidence, high-value therapeutic targets, to accelerate drug discovery

    Zyme Communications
    Dr Robert Neely CSO and Co-Founder,  Tagomics
    Healthcare and Life Science 10 Jun 2025

    Tagomics awarded £860k Innovate UK Biomedical Catalyst grant for detection of colorectal cancer

    Grant forms part of £1.2M project to customise Tagomics’ multiomic profiling platform for early detection of colorectal cancerEarly detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank
    Zyme Communications
    Centauri Therapeutics logo
    Healthcare and Life Science 10 Jun 2025

    Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections

    Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infectionsNovel bifunctional molecule based on Alphamer platform demonstrated direct, broad-spectrum antibacterial activity in vitro and in vivo, with e
    Zyme Communications
    Dr Daniel Ives, CEO, Shift Bioscience (Left), Lucas Camillo, Head of Machine Learning, Shift Bioscience (Middle), Dr Brendan Swain, CSO and Founder, Shift Bioscience (Right)
    Healthcare and Life Science 09 Jun 2025

    Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics

    SB000 reverses cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity or signs of pluripotencyStudy advances efforts towards next-generation rejuvenation therapeutics with applications across age-driven diseas
    Zyme Communications
    FUJIFILM Irvine Scientific
    Healthcare and Life Science 02 Jun 2025

    Fujifilm rebrands life sciences companies to strengthen position as strategic Partners for Life, offering end-to-end solutions

    FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences, providing a full spectrum of life sciences solutions built from a 55-year history as a cell culture pioneer FUJIFILM Diosynth Biotechnologies will be known as FUJIFILM Biotechnologies, serving global partners seek
    Zyme Communications
    Sapio logo
    Healthcare and Life Science, Science and Engineering 28 May 2025

    Sapio Sciences appoints Gordon McCall as Chief Operating Officer to drive global operational excellence

    New role underscores Sapio’s commitment to operational excellence and elevating customer delivery across global markets

    Zyme Communications
    Closed Loop Medicine logo
    Healthcare and Life Science 21 May 2025

    Closed Loop Medicine appoints Kate Woolland as CEO

    Leadership transition to drive commercialization strategy in deploying and scaling proven platform and therapy-specific precision dosing technologies

    Zyme Communications
    www.shiftbioscience.com
    Healthcare and Life Science 20 May 2025

    Shift Bioscience appoints Lord David Prior and Sir Tony Kouzarides to support long-term strategy for cell rejuvenation therapeutics

    Lord David Prior appointed as Chair of the Board, previously Chairman of NHS England and member of the UK Life Sciences Council Sir Tony Kouzarides, Co-founder and Director, Milner Therapeutics Institute, and Professor of Cancer Biology, Gurdon Institute, appointed as S
    Zyme Communications
    logo
    Healthcare and Life Science 13 May 2025

    Tozaro announces formation of Technical Advisory Board to support commercialization of Smart Polymers in cell and gene therapy bioprocessing

    World-class experts from bioprocessing and cell and gene therapy (CGT) fields include Phil Vanek PhD, Carl Schoellhammer PhD, Daniel C.
    Zyme Communications
    logo
    Healthcare and Life Science 07 May 2025

    PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

    Barbara Duncan joins as Chair and Stephen Dilly as Non-Executive DirectorStrategic appointments support progression of PhoreMost’s next generation degrader pipeline through preclinical development and commercialisation of its GlueSEEKER® platform

    Zyme Communications
    The Trilobio platform deck with a single pipette
    Healthcare and Life Science 07 May 2025

    Trilobio raises $8M to deliver whole lab automation for biologists

    San Francisco, US, 06 May 2025: Trilobio, the Company building the fully automated robotic lab-in-a-box for biologists, announces it has raised $8 million USD Seed investment.

    Zyme Communications
    Simultaneous blood samples collected upstream and downstream of coronary plaque using the Liquid Biopsy System
    Healthcare and Life Science 06 May 2025

    PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial

    Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries 

    Zyme Communications
    Dr. Jason Slingsby MBA, CEO, Tozaro	Michele Pedrocchi PhD, Non-Executive Chair, Tozaro
    Healthcare and Life Science 01 May 2025

    Tozaro appoints Dr. Jason Slingsby MBA as CEO to lead company strategy in cell and gene therapy sector

    Established biotech leader with over 20 years’ experience including at OXB and LifeArc driving commercialization to support CGT downstream manufacturingMichele Pedrocchi PhD appointed as Non-Executive Chair of the Board of Directors

    Bedfordshire

    Zyme Communications
    Sapio Sciences
    Healthcare and Life Science 29 Apr 2025

    Sapio Sciences introduces Biorepository Management Solution in Sapio Release 25.4

    Latest release of Sapio Platform streamlines sample workflows and delivers centralized, compliant biospecimen management

    Zyme Communications
    Dr Eddy Stevens, Chief Scientific Officer, Metrion Biosciences
    Healthcare and Life Science 28 Apr 2025

    Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain

    Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signallingCompletes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead and lead optimisation

    Pagination

    • First page «
    • Previous page ‹
    • …
    • Page 7
    • Page 8
    • Current page 9
    • Page 10
    • Page 11
    • …
    • Next page ›
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS